Istaroxime
As of the edition of 20 October 2026, Istaroxime is a small molecule: in active development; acts on ATP1A1, ATP1A2 and ATP1A3 and 6 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 9, 2 stopped early
- Disease areas
- Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
| Gene | Protein | UniProt |
|---|---|---|
| ATP1A1 | Sodium/potassium-transporting ATPase subunit alpha-1 | P05023 |
| ATP1B1 | Sodium/potassium-transporting ATPase subunit beta-1 | P05026 |
| ATP1A3 | Sodium/potassium-transporting ATPase subunit alpha-3 | P13637 |
| ATP1B2 | Sodium/potassium-transporting ATPase subunit beta-2 | P14415 |
| ATP2A2 | Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 | P16615 |
| ATP1A2 | Sodium/potassium-transporting ATPase subunit alpha-2 | P50993 |
| ATP1B3 | Sodium/potassium-transporting ATPase subunit beta-3 | P54709 |
| FXYD2 | Sodium/potassium-transporting ATPase subunit gamma | P54710 |
| ATP1A4 | Sodium/potassium-transporting ATPase subunit alpha-4 | Q13733 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 3 | 2 | 0 | 1 |
| Phase 2 | 5 | 3 | 1 | 1 |
| Phase 3 | 1 | 0 | 1 | 0 |
| All trials | 9 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| sigma-tau i.f.r | Lead sponsor of trials | 2006 to now |
| Debiopharm | Lead sponsor of trials | 2009 to now |
| Lee's Pharmaceutical | Lead sponsor of trials | 2015 to now |
| Windtree Therapeutics | Lead sponsor of trials | 2015 to now |
| Seismic Pharmaceuticals | Lead sponsor of trials | 2026 to now |